Introduction
Pre-eclampsia is a multisystem disorder affecting 3-5% of pregnancies and is associated with abnormal placentation and placental dysfunction (1). The detection of pre-eclampsia is a major focus of maternity care as it remains a significant cause of maternal and perinatal morbidity and mortality (1). The only treatment for pre-eclampsia currently available is delivery and therefore accurate diagnosis with the aid of a biomarker could allow adjustment to clinical care.
Placental Growth Factor (PlGF) is one of several biomarkers which have been shown to have a predictive capacity for the screening and detection of pre-eclampsia (2, 3) . PlGF is produced by the syncytiotrophoblast and is identifiable in maternal blood from as early as 12 weeks (4) with concentrations increasing with gestation until around 30 weeks before declining until birth (5) . A decline in PlGF appears to represent a negative syncytiotrophoblast stress response to a variety of insults ranging from hypoxia (6) , inflammation, oxidative stress (7) and is as such also seen as part of syncytiotrophoblast aging. PlGF concentrations are lower in pre-eclampsia (2), and extremely low in severe early-onset pre-eclampsia (8) . Recently it has also been suggested that low PlGF concentrations are associated with fetal growth restriction (FGR) (9) and placental dysfunction (10) .
Currently the National Institute for Health and Care Excellence (NICE) (11) recommends the use of two platforms for PlGF assessment in pregnancy, produced by Alere (2) and Roche (12) . The Alere platform uses antibodies against PlGF isoform-1, with some cross-reactivity for isoform-2, and has a moderate body of evidence for its clinical effectiveness at determining pre-eclampsia requiring delivery within 14 days (PELICAN study) (2, 13) . The Roche platform, which measures soluble FMS-like tyrosine kinase-1 (sFlt-1) relative to PlGF also has a developing body of evidence (PROGNOSIS study) (12) . Both tests have been endorsed by NICE for the investigation of hypertension in pregnancy, to 'rule out' a diagnosis of preeclampsia (11). Economic benefits, with savings of approximately £500 per patient, have also been suggested to be achievable if a PlGF based management pathway for women with hypertension in pregnancy is instigated (13) .
To date there have not been any published randomised controlled trials of the use of PlGF as a diagnostic test in women with hypertension in pregnancy. The best estimates of cost-effectiveness and clinical utility will come from randomised controlled trials such as the PARROT study (14) . However, until these are available comparative cohort studies may offer an insight into the clinical impact of PlGF, when used as a diagnostic test in women presenting with suspected pre-eclampsia. The objective of the MAPPLE study was to report clinical outcomes in women managed with revealed PlGF results and to compare those outcomes with those of the PELICAN study (2) in which clinicians were not informed of the PlGF result. This would identify the potential clinical implications of revealing PlGF results to the clinician.
Methods
The Management of pregnancy complications with PIGF testing (MAPPLE) registry was established as a prospective cohort of women managed with revealed PlGF results according to local guidelines as part of clinical service evaluation. Four maternity units agreed to compile data on women with pregnancies complicated by suspected pre-eclampsia or fetal growth restriction managed with revealed PlGF as part of standard maternity care and funded from within maternity budgets. Participating units were located in the United Kingdom (Liverpool), Austria (Salzburg), Germany (Osnabrück) and Australia (Adelaide).
A single 2.5ml whole blood sample was taken from each women into bottles containing ethylenediamine tetra-acetic acid. The plasma derived after centrifugation at 3000rpm for 5 mins was tested for PlGF concentration, using the Triage system (Alere, San Diego, CA), according to the manufacturer's instructions.
All meters were programmed throughout to produce a revealed PlGF result available immediately to laboratory and clinical staff. The assay uses fluorescently labelled recombinant murine monoclonal antibodies targeted to PlGF, which provide a quantifiable result within the range 12 to 3000pg/mL, within approximately 15 minutes. The manufacturer states a limit of detection of 9-3000pg/ml (11). Anonymised clinical data were entered onto a dedicated study case report form. A data transfer agreement was in place at each site before uploading to a secure database (Simplified Clinical Data Systems, Portsmouth, NH). The uploaded data were assessed for completeness by the lead author. Ethical permission was not required as no identifiable patient data were used.
Data for clinical outcomes were compared, where possible, between revealed (MAPPLE) and concealed (PELICAN) cohorts (2) using median differences or risk ratios. Only the initial PlGF assessment was used even if more than one sample was taken to maintain consistency with the PELICAN study.
The study is essentially a comparison of two cohorts of pregnant women, selected under different circumstances and for different reasons. Accordingly, we decided to conduct an unadjusted comparison between the studies, which reported on all the important measures, and estimated the size of the differences and then to adjust comparisons for the principal differences between the women prior to PlGF testing. Adjustment was made for maternal age, BMI, nulliparity, and proteinuria. For the adjusted analysis, women with twin pregnancies were excluded, as were women where key predictors were missing.
When comparing event rates (e.g. perinatal deaths, perinatal adverse outcomes, results were expressed as odds ratios, with 95% confidence intervals. For the main continuous measures birthweight and gestational age at delivery, differences in the mean were calculated. For additional measures, either means (with SD) or medians (with quartiles) were presented. Data are presented in the previously derived ranges of <12pg/ml (very low), 12-100pg/ml (low; representing <5 th percentile of normal) and >100pg/ml (normal) (2, 10).
Birthweights are presented as customised fetal weight centiles (15) . We examined whether apparent differences in infant outcomes could be due to confounding at baseline ( maternal age, singleton pregnancy, ethnicity, pre-gestational diabetes, APS/SLE, previous pregnancy complications, new hypertension, suspected FGR and proteinuria) using multiple regression. We also compared the unadjusted and adjusted impact of revealed PlGF on management of pregnant women (antenatal steroid use, induction of labour, Caesarean section) using an interaction test. The MAPPLE cohort varied from the PELICAN cohort in a number of demographic features (maternal age, twin status, ethnicity, pre-gestational diabetes, APS/SLE, and complications of previous pregnancies) as shown in Table 1 . The distribution of PlGF sub-groups at first sampling were similar.
Results

Between
There were no significant differences in maternal adverse outcomes between women in the MAPPLE cohort compared to those in the PELICAN study (11.9% vs 10.1%, Risk Ratio 1.17; 95% confidence intervals 0.76 to 1.82) with the majority of complications related to hepatic and renal dysfunction ( Table 2 ).
There were 433 babies in the MAPPLE cohort and 299 in PELICAN ( Tables 4 and 5 report maternal and perinatal outcomes for women managed with revealed and concealed testing by PlGF sub-group (<12, 12-100 and >100pg/ml). A greater proportion of women in the very low PlGF group in both cohorts had maternal adverse outcomes (compared to the other groups) and the interval from sampling to delivery was shortest in this group. As these two cohorts are not from a randomised comparison, and the cohort has been further divided, further statistical testing has not been undertaken.
All stillbirths and perinatal deaths in revealed and concealed cohorts occurred in singleton pregnancies with abnormal PlGF concentrations (low or very low) ( Table 5 ). Gestation at delivery was earliest in women with lowest PlGF concentrations, whether the result was revealed or concealed.
Discussion
In women managed with revealed PlGF results, there were fewer perinatal deaths; this may be due to modifications in surveillance and monitoring of these pregnancies than if the PlGF result were unknown.
Previous observational cohorts have demonstrated a correlation between low PlGF concentrations at 19-24
weeks' gestation and subsequent stillbirth (16) . Whilst around 25% of fetuses in both cohorts were identified as having an estimated fetal weight <10 th centile on ultrasound at presentation, there were significantly fewer infants born small for gestational age (<3 rd centile) in those managed with revealed PlGF results, even after adjustment for baseline predictors, suggesting that earlier delivery due to revealed PlGF may have prevented a slowing of fetal growth in utero. Revealing PlGF was associated with a shorter diagnosis to delivery interval and an earlier gestation at delivery. We observed a similar rate of antenatal diagnosis of SGA as the 15% observed in the sFlt1:PlGF study by Zeisler et al. (12) .
The revealing of PLGF to the clinical team was associated with a significant reduction in perinatal mortality.
Not surprisingly this gain comes at the cost of increased neonatal unit admissions and perinatal morbidity, in particular respiratory complications. This higher prevalence of respiratory morbidity in the MAPPLE cohort may be related to the earlier gestation at delivery or increased use of caesarean delivery and was not ameliorated by an increased use of antenatal steroids. Diagnosis of respiratory distress syndrome and bronchopulmonary dysplasia was similar across centres within the MAPPLE study; it was higher than that in the PELICAN study and the 10% observed in the TRUFFLE cohort of growth restricted fetuses (who share many features with women in the PlGF <12pg/ml subgroup) (17) .
Around 10% of women in both cohorts had maternal adverse outcomes, similar to previous observations (2), with the majority of adverse outcomes other than abnormal biochemistry in women with very low PlGF concentrations. There was less preeclampsia in the revealed cohort perhaps suggesting that earlier intervention prevented a worsening of the maternal condition. However, women managed with revealed PlGF results required frequent attendance at antenatal clinic and admission, possibly due to the persistence of hypertension and other risk factors.
This is the largest cohort study to date assessing the impact of PlGF informed care on pregnancy outcome and provides generalisable 'real life' data applicable across healthcare systems. At present these data 
Conclusion
Implication for practice
Our data demonstrate that PlGF-informed management of high-risk pregnancies is feasible within standard clinical care. This study was not designed to demonstrate cost-effectiveness or perform an economic analysis of the use of PlGF, but previous assessments have suggested cost savings with PlGF use. Overall, our study suggests that early intervention with PlGF-led management may prevent worsening of fetal health but at the expense of earlier delivery and increased neonatal complications, almost exclusively due to respiratory morbidity, despite increased use of antenatal steroids. This may be offset by lower perinatal mortality and fewer small for gestational age babies.
The statistically significant reduction in stillbirths between revealed and concealed PlGF led care is of interest but there should be caution in interpreting these data in light of the methodological differences between these two cohorts. Further evidence from randomised controlled trials will assist in interpretation of these findings. However, studies powered for stillbirth and perinatal death as an outcome are difficult to perform.
The pattern of earlier delivery suggests that clinicians consider optimal management and timing of delivery in response to the knowledge of PlGF. However, earlier delivery (by six days) was also associated with worsened short-term neonatal outcomes; this may have been influenced by a lower gestation at enrolment in the revealed cohort and by the overall earlier gestation at delivery of 1.4 weeks. Education of obstetric teams and increased confidence in PlGF assessment over time to ensure that PlGF use leads to increased surveillance rather than precipitating delivery may optimise the benefit (i.e. reduced perinatal death) while limiting iatrogenic delivery. Likewise, the mode of delivery should be determined by accepted obstetrical indications rather than PlGF result alone. This should be considered when planning to introduce a new tests in a high risk population.
Implications for research
The nature of this study, with different cohorts, precludes more detailed interpretation of the results in table   4 and 5. The true picture of potential clinical benefit or harm from PlGF-led management will only come from further randomised studies of its use as well as full cost-effectiveness assessment. Until the results of these studies are available, caution should be exercised before moving to PlGF-led management for all highrisk women. Ongoing and future randomised studies should have adequate power to confirm or refute our findings.
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